Clinical Trial

NMBA Reversal and Postoperative Urinary Retention

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing sugammadex with neostigmine (combined with a muscarinic antagonist), and postoperative urinary retention (POUR) will be evaluated. In secondary analyses, the effects of NMBA reversal strategy and POUR on costs of care and unplanned hospital visits will be analyzed.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-19.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-01-21
Trial Details
NCT Number NCT06948409
Lead Sponsor Beth Israel Deaconess Medical Center
Conditions Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex +3 more
Enrollment 70,000 participants
Start Date 2025-06-08
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-23